FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052150902> ?p ?o ?g. }

• W2052150902 endingPage "45" @default.
• W2052150902 startingPage "45" @default.
• W2052150902 abstract "TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation Julio Pascual,1 Titte R Srinivas,2 Steven Chadban,3 Franco Citterio,4 Federico Oppenheimer,5 Helio Tedesco,6 Mitchell Henry,7 Christophe Legendre,8 Yoshihiko Watarai,9 Claudia Sommerer,10 Po-Chang Lee,11 J Mark Hexham,12 Gaohong Dong,12 Peter Bernhardt,13 Flavio Vincenti14 1Nephrology Department, Hospital del Mar, Barcelona, Spain; 2Division of Nephrology, Medical University of South Carolina, Mt Pleasant, SC, USA; 3Department of Transplantation, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; 4Centro Trapianti d'Organo Istituto di Clinica Chirurgica, Università Cattolica del Sacro Cuore, Policlinico Universitario A Gemelli, Rome, Italy; 5Renal Transplant Unit, Hospital Clínic de Barcelona, Barcelona, Spain; 6Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, Brazil; 7The Comprehensive Transplant Center, The Ohio State University, Wexner Medical Center, Columbus, OH, USA; 8Service de Transplantation Adultes, Université Paris Descartes and Hôpital Necker, Paris, France; 9Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya City, Aich, Japan; 10Medizinische Klinik, Sektion Nephrologie, Universitätsklinikum Heidelberg, Heidelberg, Germany; 11Medical College, National Cheng Kung University, Tainan City, Taiwan; 12Biometrics and Statistical Science, Novartis Pharmaceuticals, East Hanover, NJ, USA; 13Research and Development, Novartis Pharma AG, Basel, Switzerland; 14Kidney Transplant Service, University of California San Francisco, San Francisco, CA, USA Abstract: Two well defined, modifiable risk factors for kidney allograft failure are acute rejection and poor graft function at one year post-transplant. Regulatory bodies and expert panels in the USA and Europe have recognized that both acute rejection and one-year graft function should be assessed when evaluating immunosuppressive regimens. TRANSFORM (Clinicaltrials.gov NCT01950819) is one of the first trials to adopt this approach and the first that applies a novel combined clinically meaningful endpoint to take the first step towards changing the paradigm for immunosuppression in kidney transplant patients. Everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy is a strategy designed to reduce the risk of chronic nephrotoxicity and other dose-dependent complications associated with CNI therapy. In TRANSFORM, de novo kidney transplant patients are randomized to everolimus with reduced-exposure CNI, or mycophenolic acid with standard-exposure CNI, both with induction therapy and maintenance steroids. The primary endpoint is a composite of treated biopsy-proven acute rejection or estimated glomerular filtration rate ,50 mL/min/1.73 m2 at month 12 post-transplant, which is expected to be sensitive both to the effects of acute and chronic allograft rejection and nephrotoxic side effects of immunosuppressive therapies. The construct of this endpoint allows the integration of a continuous outcome (graft function) with a logistic outcome (rejection). The trial uses a randomized, multicenter, open-label, two-arm design. After completion of a 2-year core study, patients enter a further 3-year prospective observational study. By capturing follow-up to 5 years, TRANSFORM will provide substantial data on the incidence of graft loss, graft dysfunction, cancer, cardiovascular events, and other patient-relevant outcomes. TRANSFORM will determine whether de novo CNI reduction with an everolimus-based regimen achieves short-term outcomes compared with standard CNI. As the largest clinical trial undertaken to date in kidney transplantation, recruiting more than 2,000 patients, and with extended follow-up to 5 years, TRANSFORM will provide critical data required to help maximize long-term outcomes. Keywords: mTOR inhibitor, calcineurin inhibitor, reduced exposure" @default.
• W2052150902 created "2016-06-24" @default.
• W2052150902 creator A5009588333 @default.
• W2052150902 creator A5019416771 @default.
• W2052150902 creator A5021421627 @default.
• W2052150902 creator A5026789430 @default.
• W2052150902 creator A5031374373 @default.
• W2052150902 creator A5044623478 @default.
• W2052150902 creator A5055415519 @default.
• W2052150902 creator A5070667307 @default.
• W2052150902 creator A5073214741 @default.
• W2052150902 creator A5073772726 @default.
• W2052150902 creator A5081734578 @default.
• W2052150902 creator A5082048763 @default.
• W2052150902 creator A5082982321 @default.
• W2052150902 creator A5088108322 @default.
• W2052150902 creator A5090121520 @default.
• W2052150902 date "2014-06-01" @default.
• W2052150902 modified "2023-10-16" @default.
• W2052150902 title "TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation" @default.
• W2052150902 cites W1524392977 @default.
• W2052150902 cites W1560618174 @default.
• W2052150902 cites W1588788406 @default.
• W2052150902 cites W1590390166 @default.
• W2052150902 cites W1594636479 @default.
• W2052150902 cites W1596082572 @default.
• W2052150902 cites W1600996638 @default.
• W2052150902 cites W1755633921 @default.
• W2052150902 cites W1883239790 @default.
• W2052150902 cites W193040257 @default.
• W2052150902 cites W1963859566 @default.
• W2052150902 cites W1970425640 @default.
• W2052150902 cites W1978363322 @default.
• W2052150902 cites W1987532648 @default.
• W2052150902 cites W1989398460 @default.
• W2052150902 cites W1990622186 @default.
• W2052150902 cites W1995450339 @default.
• W2052150902 cites W1998756277 @default.
• W2052150902 cites W2000042169 @default.
• W2052150902 cites W2000453285 @default.
• W2052150902 cites W2001808867 @default.
• W2052150902 cites W2007705521 @default.
• W2052150902 cites W2009483242 @default.
• W2052150902 cites W2010330416 @default.
• W2052150902 cites W2011557997 @default.
• W2052150902 cites W2020368170 @default.
• W2052150902 cites W2021137320 @default.
• W2052150902 cites W2032706825 @default.
• W2052150902 cites W2033382768 @default.
• W2052150902 cites W2041926636 @default.
• W2052150902 cites W2044902610 @default.
• W2052150902 cites W2049621438 @default.
• W2052150902 cites W2052098973 @default.
• W2052150902 cites W2053225580 @default.
• W2052150902 cites W2055864845 @default.
• W2052150902 cites W2055977064 @default.
• W2052150902 cites W2056252610 @default.
• W2052150902 cites W2059225925 @default.
• W2052150902 cites W2070028090 @default.
• W2052150902 cites W2072285198 @default.
• W2052150902 cites W2090106968 @default.
• W2052150902 cites W2101302191 @default.
• W2052150902 cites W2104307363 @default.
• W2052150902 cites W2107218339 @default.
• W2052150902 cites W2122783053 @default.
• W2052150902 cites W2134672034 @default.
• W2052150902 cites W2140501857 @default.
• W2052150902 cites W2142966586 @default.
• W2052150902 cites W2148223163 @default.
• W2052150902 cites W2153904763 @default.
• W2052150902 cites W2154847999 @default.
• W2052150902 cites W2159435196 @default.
• W2052150902 cites W2198308217 @default.
• W2052150902 cites W2321487929 @default.
• W2052150902 cites W2322193260 @default.
• W2052150902 cites W2324368852 @default.
• W2052150902 cites W2337109902 @default.
• W2052150902 doi "https://doi.org/10.2147/oajct.s63058" @default.
• W2052150902 hasPublicationYear "2014" @default.
• W2052150902 type Work @default.
• W2052150902 sameAs 2052150902 @default.
• W2052150902 citedByCount "16" @default.
• W2052150902 countsByYear W20521509022015 @default.
• W2052150902 countsByYear W20521509022016 @default.
• W2052150902 countsByYear W20521509022017 @default.
• W2052150902 countsByYear W20521509022018 @default.
• W2052150902 countsByYear W20521509022019 @default.
• W2052150902 countsByYear W20521509022020 @default.
• W2052150902 countsByYear W20521509022021 @default.
• W2052150902 crossrefType "journal-article" @default.
• W2052150902 hasAuthorship W2052150902A5009588333 @default.
• W2052150902 hasAuthorship W2052150902A5019416771 @default.
• W2052150902 hasAuthorship W2052150902A5021421627 @default.
• W2052150902 hasAuthorship W2052150902A5026789430 @default.
• W2052150902 hasAuthorship W2052150902A5031374373 @default.
• W2052150902 hasAuthorship W2052150902A5044623478 @default.
• W2052150902 hasAuthorship W2052150902A5055415519 @default.
• W2052150902 hasAuthorship W2052150902A5070667307 @default.

• next